Welcome to our dedicated page for Galecto news (Ticker: GLTO), a resource for investors and traders seeking the latest updates and insights on Galecto stock.
Galecto Inc. (GLTO) reports biotechnology developments tied to hematologic disorders and blood cancers, including mutant calreticulin myeloproliferative neoplasms. Company updates center on antibody programs such as DMR-001, a mutant calreticulin-targeting monoclonal antibody, and additional pipeline candidates including DMR-002, along with clinical, regulatory, manufacturing, and research-and-development priorities.
Recurring news also covers equity financings, preferred-stock and common-stock capital actions, inducement grants under Nasdaq rules, shareholder voting matters, leadership changes, governance updates, operating results, and participation in healthcare investor conferences.
Galecto, Inc. announced the enrollment of the first patient in an investigator-initiated Phase 2 trial to evaluate GB1211, a galectin-3 inhibitor, in combination with pembrolizumab for metastatic melanoma and head and neck squamous cell carcinoma. Galecto aims to explore GB1211's potential to enhance the effectiveness of pembrolizumab in various cancer indications.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.